Real-world Outcomes of Durvalumab Consolidation in Elderly Patients With Unresectable NSCLC Following CCRT With Daily Low-dose Carboplatin
Anticancer Research · 2025
DOI: 10.21873/anticanres.17425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Keijiro Yamauchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan keijiro2024@outlook.com. Hauptthemen laut MEDLINE: Carboplatin, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, Lung Neoplasms.
Abstract (Originalsprache)
BACKGROUND/AIM: The clinical benefits of durvalumab consolidation therapy following concurrent chemoradiotherapy (CCRT) with daily low-dose carboplatin in elderly patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) remain unclear. PATIENTS AND METHODS: This was a single-institution retrospective cohort study. We analyzed the medical records of consecutive patients diagnosed with NSCLC who received CCRT with daily low-dose carboplatin from April 2014 to March 2021. Outcomes were compared between the overall group and two subgroups: those who received durvalumab consolidation therapy (CCRT-durvalumab group) and those who did not (CCRT-alone group). The primary endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: A total of 38 patients (median age: 76 years) were enrolled in this study. The median PFS was 9.9 months in the overall group, 11.7 months in the CCRT-durvalumab group, and 10.2 months in the CCRT-alone group. The median OS was 39.4 months in the overall group, 32.0 months in the CCRT-durvalumab group, and 39.4 months in the CCRT-alone group. There were no significant differences between the two subgroups in terms of PFS [hazard ratio (HR)=0.88, p=0.97] or OS (HR=1.21, p=0.70). CONCLUSION: In real-world settings, durvalumab consolidation therapy following CCRT with daily low-dose carboplatin does not appear to provide clinical benefits in terms of PFS or OS for elderly patients with unresectable, locally advanced NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan keijiro2024@outlook.com.
- Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Zitieren
APA
Yamauchi, K., Komuta, R., Tanabe, H., Yokoyama, M., Takata, S. O., Yanase, T., Hosono, Y., Satoh, S., Morishita, N., & Suzuki, H. (2025). Real-world Outcomes of Durvalumab Consolidation in Elderly Patients With Unresectable NSCLC Following CCRT With Daily Low-dose Carboplatin. Anticancer Research. https://doi.org/10.21873/anticanres.17425
Vancouver
Yamauchi K, Komuta R, Tanabe H, Yokoyama M, Takata SO, Yanase T, et al. Real-world Outcomes of Durvalumab Consolidation in Elderly Patients With Unresectable NSCLC Following CCRT With Daily Low-dose Carboplatin. Anticancer Research. 2025. doi:10.21873/anticanres.17425
BibTeX
@article{Yamauchi2025,
author = {Yamauchi, Keijiro and Komuta, Riiko and Tanabe, Hidetaka and Yokoyama, Masashi and Takata, S O and Yanase, Takafumi and Hosono, Yuki and Satoh, Shingo and Morishita, Naoko and Suzuki, Hidekazu},
title = {Real-world Outcomes of Durvalumab Consolidation in Elderly Patients With Unresectable NSCLC Following CCRT With Daily Low-dose Carboplatin},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17425}
}
EUVIMED